Consensus Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Real-time Estimate Cboe BZX Other stock markets 09:51:35 2024-05-01 EDT			5-day change	1st Jan Change
25.34 ^USD	+0.26%		+73.26%	+57.04%

12:13pm	North American Morning Briefing : Traders Wait for -2-	DJ
04-30	Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	MT

Evolution of the average Target Price on Deciphera Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6510dd97fc24980a1134f10b6aa.mkBgcl2USMJuBEunPOfAcBvrrkCcX6eVZOnLy46HmKw.6Ck4IGv1AaghVBvEBYGrGUKl_iiqK5WtXJynk_3p3tr7CwxLNqUepyk9JA~a13f677592b84c7db9acb57af4e2665d

Analyst Recommendations on Deciphera Pharmaceuticals, Inc.

Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	04-30	MT
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	04-30	MT
JMP Downgrades Deciphera Pharmaceuticals to Market Perform	04-30	MT
JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	04-29	MT
Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	04-29	MT
North American Morning Briefing : Rate Doubts Keep -2-	02-06	DJ
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	01-18	MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $30 From $25, Keeps Buy Rating	23-10-31	MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Buy From Hold, $16 Price Target	23-10-31	MT
Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight From Neutral, Raises Price Target to $23 From $18	23-10-30	MT
Stifel Upgrades Deciphera Pharmaceuticals to Buy From Hold, Adjusts Price Target to $20 From $14	23-08-10	MT
HC Wainwright Reiterates Deciphera Pharmaceuticals at Buy With $25 Price Target	23-02-08	MT
SVB Securities Adjusts Deciphera Pharmaceuticals Price Target to $30 From $28, Maintains Outperform Rating	23-02-07	MT
Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outperform Rating	23-01-25	MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Hold From Sell	23-01-06	MT
SVB Securities Raises Price Target on Deciphera Pharmaceuticals to $28 From $25, Keeps Outperform Rating	23-01-04	MT
Barclays Adjusts Deciphera Pharmaceuticals Price Target to $9 From $8, Maintains Underweight Rating	23-01-04	MT
Guggenheim Upgrades Deciphera Pharmaceuticals to Buy From Neutral, Price Target is $22	23-01-04	MT
Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating	22-09-27	MT
Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating	22-09-12	MT
SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating	22-09-12	MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterates Buy Rating	22-09-12	MT
Deciphera Pharmaceuticals Shares Rise After Cowen Initiates Coverage	22-08-29	MT
Cowen Starts Deciphera Pharmaceuticals at Outperform With $25 Price Target	22-08-29	MT
HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiterates Buy Rating	22-08-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.27 USD

Average target price

26.38 USD

Spread / Average Target

+4.38%

High Price Target

30 USD

Spread / Highest target

+18.72%

Low Price Target

23 USD

Spread / Lowest Target

-8.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Deciphera Pharmaceuticals, Inc.

JMP Securities
Leerink Partners
Barclays
JonesTrading Institutional Services
Jefferies & Co.
HC Wainwright
Piper Sandler
Stifel Nicolaus
SVB Securities LLC
Cowen
Guggenheim
Truist Securities
Canaccord Genuity
JPMorgan Chase
Credit Suisse
SVB Leerink

Ratings for Deciphera Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar